

A RARE CASE OF CUTANEOUS ADVERSE DRUG REACTION OF AZITHROMYCIN: A CASE REPORT

ABSTRACT:

Azithromycin, a macrolide antibiotic, an azalide derivative of erythromycin, is a Schedule H drug that can be procured from pharmacies in India only with a prescription. Despite the strict regulations, it is commonly available as an over-the-counter (OTC) medication in most pharmacies in India. A 33-year-old male had complaints of fever and sore throat, for which he self-administered tablet Azithromycin 500 mg once daily for three days. Two days after the last dose, he noticed the development of an itchy, erythematous rash. He was diagnosed with acute generalised exanthematous pustulosis (AGEP). Azithromycin was discontinued immediately, and he was treated in the ICU with corticosteroids and antihistamines. Acute Generalised Exanthematous Pustulosis (AGEP) is a rare and self-limiting Severe Cutaneous Adverse Reaction (SCAR) induced by medications. It presents with the rapid appearance of numerous non-follicular, sterile pustules on a widespread erythematous base, often accompanied by fever and neutrophilic leukocytosis. This case highlights the potential for azithromycin, a commonly used and generally well-tolerated antibiotic, to induce rare but significant cutaneous reactions such as AGEP. Clinicians should remain vigilant when prescribing antibiotics, especially in patients who present with new-onset rashes during or after therapy.

KEYWORDS: Acute Generalised Exanthematous Pustulosis, Azithromycin, Severe Cutaneous Adverse Reaction, Over-the-counter medication.

WORD COUNT:741(Excluding abstract, keywords & references)

INTRODUCTION:

Macrolide antibiotics are frequently prescribed in clinics and hospitals for a wide range of infections. Azithromycin, a macrolide antibiotic, an azalide derivative of erythromycin, is a Schedule H drug that can be procured from pharmacies in India only with a prescription. Despite the strict regulations, it is commonly available as an over-the-counter (OTC) medication in most of pharmacies in India. It is usually prescribed in a once-daily dosage due to its long half-life of more than 50 hours¹. Common adverse reactions with azithromycin include gastrointestinal disturbances. Hypersensitivity reactions to azithromycin are relatively rare and typically mild, with an incidence of 0.4% to 3%². This case describes one such rare case of a hypersensitivity reaction after taking Azithromycin in an otherwise healthy adult male.

CASE DETAILS:

A 33-year-old male had complaints of fever and sore throat, for which he self-administered tablet Azithromycin 500 mg once daily for three days. Two days after the last dose, he noticed the development of an itchy, erythematous rash, for which he visited a dermatologist. On examination, the patient had multiple grouped, pinpoint-to-pinhead-sized pustules on an erythematous base, along with skin exfoliation over the neck, chest, abdomen (Figure 1), back, axillae, groin, and extremities (Figure 2). He was hemodynamically stable and afebrile. Auscultation revealed clear lungs; abdominal examination was unremarkable with no hepatosplenomegaly. The patient denied any

48 prior history of drug allergies or similar reactions. No family history of drug
49 hypersensitivity was reported.

50

51

Figure 1: Pustular exfoliative lesions

Figure 2: Exfoliative lesion over left palm

52



54

55 He was diagnosed with acute generalised exanthematous pustulosis (AGEP).
56 Azithromycin was discontinued immediately. The patient was admitted to the ICU for
57 observation and was started on prednisolone 10 mg TDS for two days, tapered gradually
58 to once daily over the next six days. He also received levocetirizine 5 mg daily for one
59 week, along with a moisturiser lotion applied twice daily for skin hydration. Within 48
60 hours of treatment initiation, significant improvement in skin lesions was observed, and
61 complete resolution occurred within one week without residual pigmentation or scarring.

62

63

64

65

DISCUSSION:

66

67

68

69

70

71

72

73

74

75

76

77

78

Acute Generalised Exanthematous Pustulosis (AGEP) is a rare and self-limiting Severe Cutaneous Adverse Reaction (SCAR) induced by medications. It presents with the rapid appearance of numerous non-follicular, sterile pustules on a widespread erythematous base, often accompanied by fever and neutrophilic leukocytosis. Diagnosis is primarily clinical but can be supported by histopathological findings and a temporal association with drug exposure^{3,4}. The pathophysiology of AGEP is thought to involve Type IV hypersensitivity, a delayed T-cell-mediated immune response. Drug-specific CD4+ and CD8+ T cells are activated and secrete interleukin-8 (IL-8), a potent chemoattractant for neutrophils. This leads to an influx of neutrophils into the dermis and epidermis, resulting in sterile pustule formation^{5,6}.

AGEP is mostly associated with β -lactam antibiotics and antimalarials. Macrolides like azithromycin have been rarely implicated in SCARs. Dakdouki et al. reported a maculopapular rash in a patient with infectious mononucleosis after

79 azithromycin intake, emphasising the possibility of immune interactions unique to viral-
80 bacterial-drug overlaps⁷. Schissel et al. described a delayed exanthematous reaction to
81 azithromycin in the context of Epstein-Barr virus infection, suggesting that even a
82 commonly prescribed drug may exhibit unpredictable immunogenicity in certain
83 hosts⁸. Although our patient had no evidence of viral co-infection, these reports reinforce
84 the necessity of clinical suspicion even in cases without underlying immunological triggers.

85 Severe cutaneous reactions to azithromycin have also been documented. Trevisi et
86 al. described a case of toxic pustuloderma appearing just 16 hours after drug
87 administration, which bears a close resemblance to AGEP but often involves deeper
88 dermal involvement and more prominent systemic symptoms⁹. In contrast, Saito-Sasaki et
89 al. reported a purpuric eruption following azithromycin use, highlighting a vasculitic
90 component not typically seen in AGEP¹⁰. These cases help contextualise our findings by
91 demonstrating that azithromycin may provoke a spectrum of dermatological reactions,
92 from mild exanthema to pustular or purpuric eruptions. Our case stands out due to the
93 classic AGEP morphology, relatively late onset after 72 hours of azithromycin use, and
94 complete resolution with corticosteroid therapy, underscoring the diversity of clinical
95 presentations associated with this drug.

96 97 **CONCLUSION:**

98 This case highlights the potential for azithromycin, a commonly used and generally well-
99 tolerated antibiotic, to induce rare but significant cutaneous reactions such as AGEP.
100 Clinicians should remain vigilant when prescribing antibiotics, especially in patients who
101 present with new-onset rashes during or after therapy. Early recognition and timely
102 intervention can prevent complications and hasten recovery.

103 104 **DISCLOSURE:**

105 Written Informed consent was obtained from the patient for publication of this case
106 report and associated images.

107 108 **CONFLICT OF INTEREST: NIL**

109 110 **FINANCIAL SUPPORT: NIL**

111 112 113 114 **REFERENCES:**

- 115
116 1. Tripathi KD. Essentials of Medical Pharmacology. 8th ed. Jaypee Brothers Medical
117 Publishers; 2019.
- 118 2. Shaer KM, Chahine EB, Gupta SV, Cho JC. Macrolide allergic reactions. Pharmacy
119 (Basel). 2019;7(3):135.
- 120 3. Pereira HP, Lopes JC, Carrapatoso I, Faria E, Todo-Bom A. Immediate-
121 hypersensitivity reactions to macrolides: experience in an allergy department. Asia
122 Pac Allergy. 2024;14(3):152–154.

- 123 4. Campanón-Toro MV, et al. Acute generalized exanthematous pustulosis (AGEP)
124 induced by azithromycin. *Contact Dermatitis*. 2017;76(6).
- 125 5. Britschgi M, Pichler WJ. Delayed drug hypersensitivity reactions. *Curr Opin Allergy*
126 *Clin Immunol*. 2002;2(4):301–306.
- 127 6. Feldmeyer L, Heidemeyer K, Yawalkar N. AGEP: pathogenesis, genetic background,
128 clinical variants and therapy. *Int J Mol Sci*. 2016;17(8):1214.
- 129 7. Dakdouki GK, Obeid KH, Kanj SS. Azithromycin-induced rash in infectious
130 mononucleosis. *Scand J Infect Dis*. 2002;34(12):939–941.
- 131 8. Schissel DJ, Singer D, David-Bajar K. Azithromycin eruption in infectious
132 mononucleosis: a proposed mechanism. *Cutis*. 2000;65(3):163–166.
- 133 9. Trevisi P, Patrizi A, Neri I, Farina P. Toxic pustuloderma associated with
134 azithromycin. *Clin Exp Dermatol*. 1994;19(3):280–281.
- 135 10. Saito-Sasaki N, Sawada Y. Purpuric drug eruption caused by azithromycin: a case
136 report and literature review. *Cureus*. 2024;16(2).

137
138
139
140
141
142
143
144
145
146
147

UNDER PEER REVIEW IN IJAR